Search Results for: Un gel intelligente per attaccare il cancro

Per nati 1990 rischio doppio di cancro colon

Dal melanoma al tumore del polmone, dal cancro al seno triplo negativo a quello del colon-retto e della vescica: sono sempre più numerosi i tumori per cui la somministrazione dell’immunoterapia neoadiuvante, cioè del trattamento prima dell’intervento chirurgico, mostra evidenze di maggiore efficacia. Questa nuova evoluzione dell’immunoterapia è al centro della seconda edizione di “I.N.N.O.VA.T.E. – International Neoadjuvant Immunotherapy Across Cancers”, al via oggi, e fino a domani, a Napoli.

L’Agenzia Italiana del Farmaco (Aifa) ha riconosciuto la rimborsabilità di un’ulteriore indicazione terapeutica per enzalutamide, sulla base dei risultati dello studio di Fase 3 EMBARK. Con questa autorizzazione enzalutamide diventa il primo ed unico inibitore del segnale del recettore degli androgeni che ha ottenuto la rimborsabilità per il trattamento di uomini adulti con cancro della prostata non metastatico ormono-sensibile (nmHSPC) con recidiva biochimica (BCR) ad alto rischio non idonei alla radioterapia di salvataggio

Ricercatori Biogem, si apre la strada a cure mirate

Ricercatori Biogem, si apre la strada a cure mirate

We read the study conducted by Drews et al1 with great interest. In this prospective randomised controlled trial of patients undergoing hot-snare EMR of flat lesions in the duodenum (≥10 mm) and colorectum (≥20 mm) at 15 German centres, the authors conclude that the application of a haemostatic gel (Purastat, 3-D Matrix Europe SAS) following EMR in both locations does not reduce the rate of delayed bleeding (DB). From a conceptual perspective, combining two anatomical sites with likely different pathophysiologies of DB and different bleeding rates and assuming the likely percentage distribution spread for the lesion location of the cases enrolled seems to us to be a suboptimal design for a randomised clinical trial. Aside from this design, which could be subject to debate, our main objection to the trial is the sample size calculation. Reviewing the results of the three colonic RCTs referenced by the authors

Consentirà di personalizzare cure sin dal momento della diagnosi

In campo squadre dei Centri oncoematologia pediatrica d’Italia

Background
Prophylactic application of a haemostatic gel to the resection field may be an easy way to prevent delayed bleeding, a frequent complication after endoscopic mucosal resection (EMR).

Objective
We aimed to evaluate if the prophylactic application of a haemostatic gel to the resection field directly after EMR can reduce the rate of clinically significant delayed bleeding events.

Design
We conducted a prospective randomised trial of patients undergoing hot-snare EMR of flat lesions in the duodenum (≥10 mm) and colorectum (≥20 mm) at 15 German centres. Prophylactic clip closure was not allowed, but selective clipping or coagulation could be used prior to randomisation to treat intraprocedural bleeding or for prophylactic closure of visible vessels. Patients were randomised to haemostatic gel application or no prophylaxis. The primary endpoint was delayed bleeding within 30 days.

Results
The trial was stopped early due to futility after an interim analysis. The primary endpoint was analysed in 232 patients (208 colorectal, 26 duodenal). Both groups were comparable in age, sex, comorbidities and lesion characteristics. Preventive measures, such as selective clipping or coagulation, were applied prior to randomisation in 51.9% of cases, with no difference between groups. Delayed bleeding occurred in 14 cases (11.7%; 95% CI 7.1% to 18.6%) after Purastat and in 7 cases (6.3%; 95% CI 3.1% to 12.3%) in the control group (p=0.227), with no difference between colorectal and duodenal subgroups.

Conclusion
The application of a haemostatic gel following EMR of large flat lesions in the duodenum and colorectum does not reduce the rate of delayed bleeding.

Background
Prophylactic application of a haemostatic gel to the resection field may be an easy way to prevent delayed bleeding, a frequent complication after endoscopic mucosal resection (EMR).

Objective
We aimed to evaluate if the prophylactic application of a haemostatic gel to the resection field directly after EMR can reduce the rate of clinically significant delayed bleeding events.

Design
We conducted a prospective randomised trial of patients undergoing hot-snare EMR of flat lesions in the duodenum (≥10 mm) and colorectum (≥20 mm) at 15 German centres. Prophylactic clip closure was not allowed, but selective clipping or coagulation could be used prior to randomisation to treat intraprocedural bleeding or for prophylactic closure of visible vessels. Patients were randomised to haemostatic gel application or no prophylaxis. The primary endpoint was delayed bleeding within 30 days.

Results
The trial was stopped early due to futility after an interim analysis. The primary endpoint was analysed in 232 patients (208 colorectal, 26 duodenal). Both groups were comparable in age, sex, comorbidities and lesion characteristics. Preventive measures, such as selective clipping or coagulation, were applied prior to randomisation in 51.9% of cases, with no difference between groups. Delayed bleeding occurred in 14 cases (11.7%; 95% CI 7.1% to 18.6%) after Purastat and in 7 cases (6.3%; 95% CI 3.1% to 12.3%) in the control group (p=0.227), with no difference between colorectal and duodenal subgroups.

Conclusion
The application of a haemostatic gel following EMR of large flat lesions in the duodenum and colorectum does not reduce the rate of delayed bleeding.

Ostacoli anche dai prontuari terapeutici. Ritardi territoriali per la cura innovativa nel cancro della prostata

“Abbiamo capito che non esistono cure miracolose”